GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Sale Of Business

NurExone Biologic (FRA:J90) Sale Of Business : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Sale Of Business?

NurExone Biologic's sale of business for the three months ended in Jun. 2024 was €0.00 Mil. It means NurExone Biologic gained €0.00 Mil from selling business. NurExone Biologic's sale of business for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Mar. 2024 ), NurExone Biologic gained the same money from selling business in Jun. 2024 (€0.00 Mil).


NurExone Biologic Sale Of Business Historical Data

The historical data trend for NurExone Biologic's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Sale Of Business Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
Sale Of Business
- - -

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NurExone Biologic Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NurExone Biologic Sale Of Business Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines